This website uses cookies to improve user experience. By continuing to use this website, you consent to our use of these cookies. To learn more about how we use and manage cookies, see our Privacy Policy and Cookie Policy.
Most patients with HAE experience angioedema attacks because they lack functioning C1-INH. BERINERT replaces missing or dysfunctional C1-INH through an intravenous infusion, which quickly restores their C1-INH levels.
C1-INH inactivates C1, thereby stopping the production of proteolytic fragments and inflammation-inducing complexes.
C1-INH inhibits plasmin, thus inhibiting fibrin degradation.
C1-INH prevents the conversion of prekallikrein to kallikrein—and the subsequent formation of bradykinin.
C1-INH inhibits Factors XIIa and XIa.
Watch a presentation about the physiological function of C1-INH and how C1-INH replacement therapy treats the root cause of HAE attacks.
A single dose of BERINERT IV provides a rapid increase in C1-INH levels*
*In a prospective, randomized, open-label, crossover study, 23 subjects with mild or moderate HAE received a single dose of BERINERT (1000 units) IV or SC during an attack-free interval.5
| Adults (n=35) |
Children§ (n=5) |
|
|---|---|---|
| AUC(0–t) (hr x IU/mL)‡ | 12.8 | 9.78 |
| Clearance (mL/hr/kg) | 1.44 | 1.9 |
| Volume at steady state (mL/kg) | 35.4 | 38.8 |
| Half-life (hr) | 18.4 | 16.7 |
| Mean residence time (hr) | 26.4 | 24.0 |
†Adjusted for baseline.
‡Based on 15 IU/kg dose.
§Age range: 6–13 years.
